Creating oligonucleotide medicines delivered to the kidney, silencing target genes to treat systemic and renal diseases. Raised $100M Series A (Atlas, TCG, Droia, Digitalis).

Harnessing power of nutrition to address major unmet medical needs

Oligonucleotide therapeutic platform addressing multiple unmet patient needs

Strategic advisor to stealth mode neuropsychiatry biotech

Transitioned to Chairman of Board 8/1/23 after 10 years as Founder and CEO. Developing novel treatments for serious infections. Built team responsible for 11 approved antibacterial drugs and raised $400M across private financings, IPO, public financings, and partnerships. Advanced three programs into late stage clinical trials. Completed $600M partnership with GSK for worldwide commercialization of tebipenem, and partnerships with Pfizer (SPR206) and Roche. Awarded over $100M in federal grants from NIH, BARDA, and US Department of Defense. Winner of 2017 Xconomy Startup of the Year, 2015 Fierce 15 Award, and 2017, 2020, and 2021 Best Places to Work Award. Winner of Glassdoor 2021 Top 50 CEOs Nationwide, Small and Medium Enterprises.

Applying machine learning to compound optimization

Developing next generation treatments for serious psychiatric disorders

Early stage life sciences and technology venture capital firm. Served as investment team member (2008-13), Venture Partner (2013-22), and Advisor (2022-23). Currently serve as BOD member for Atlas portfolio company.

Co-founder of next generation synthetic biology company inspired by the discoveries of Jim Collins and Tim Lu (Nasdaq: SYBX). Developing therapeutic microbes addressing high unmet medical needs, with the ability to tune therapeutic output based on environmental factors. As Acting CEO, secured seed investment from Atlas Venture in Fall 2013, and $30.4M Series A led by Atlas Venture, New Enterprise Associates, and the Gates Foundation in July 2014. Also completed multi-year R & D Collaboration with Abbvie. www.synlogictx.com

Developing therapies leveraging epigenetic mechanisms for treatment of unmet medical needs in the neurosciences. As Acting CEO, secured equity investment and collaboration with Johnson and Johnson Innovation Center in May 2013. Raised $12.9MM Series A Financing in May 2014, and completed $500M collaboration with Biogen.www.rodintherapeutics.com

VC representative of advisory board guiding program decision making. Co-chair of Pharma/VC collaborations subcommittee.

Leveraging proprietary platform to develop therapeutics for gene up-regulation. Closed $20.5M Series A Financing with Atlas, SR One, and Monsanto.

Creating safer, more effective therapies for anesthesia and critical care. Closed investment and Option deal with The Medicines Company in September 2012. Company acquired by The Medicines Company in January 2015.

Developing anti-CGRP antibody for treatment of chronic migraine. Raised $18M from Atlas and Orbimed; secured license to asset and option deal with Eli Lilly. Antibody acquired by Eli Lilly in January 2014.

Developing topical therapies for neuropathic pain